Traynor Capital Management, Inc.
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 1666786
MALVERN, PA
Position in ALNY
as of Jun 30, 2026
· filed Jul 22, 2026
Position Value
$3,148,171
-$1,018,144 QoQ
Shares Held
10,458
-16.9% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
#275
of 780 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Traynor Capital Management, Inc. holds $9,749,803 across 5 Biotechnology names. ALNY ranks #2 (32.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
9,049 | $4,494,909 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
10,458 | $3,148,171 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,005 | $1,873,737 | |
| 4 | IBRX |
ImmunityBio, Inc.
|
19,200 | $168,096 | |
| 5 | NGEN |
Nervgen Pharma Corp.
|
31,500 | $64,890 |
All Filings in ALNY
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,148,171 | 10,458 | Shares | Sole | 2026-07-22 | |
| 2026-03-31 | $4,166,315 | 12,592 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $4,600,810 | 11,570 | Shares | Sole | 2026-01-12 | |
| 2025-09-30 | $4,958,088 | 10,873 | Shares | Sole | 2025-11-03 | |
| 2025-06-30 | $3,327,748 | 10,205 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $2,655,106 | 9,833 | Shares | Sole | 2025-05-12 | |
| 2024-12-31 | $2,200,148 | 9,350 | Shares | Sole | 2025-01-17 | |
| 2024-09-30 | $1,993,692 | 7,249 | Shares | Sole | 2024-10-25 | |
| No filing history on record for this holder in this stock. | ||||||